Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry

Oksana A. Shlobin, Vasilis Kouranos, Scott D. Barnett, Esam H. Alhamad, Daniel A. Culver, Joseph Barney, Francis C. Cordova, Eva M. Carmona, Mary Beth Scholand, Marlies Wijsenbeek, Sivagini Ganesh, Elyse E. Lower, Peter J. Engel, John Wort, Laura Price, Athol U. Wells, Steven D. Nathan, Robert P. Baughman
European Respiratory Journal 2020; DOI: 10.1183/13993003.01747-2019
Oksana A. Shlobin
1INOVA Fairfax Hospital, Falls Church, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Oksana.shlobin@inova.org
Vasilis Kouranos
2Royal Hospital Brompton, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott D. Barnett
1INOVA Fairfax Hospital, Falls Church, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esam H. Alhamad
3King Saud University, Riyadh, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel A. Culver
4Cleveland Clinic, Cleveland, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Barney
5University of Alabama, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis C. Cordova
6Temple University, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva M. Carmona
7Mayo Clinic, Rochester, Minn, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Beth Scholand
8University of Utah, Salt Lake City, Utah, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marlies Wijsenbeek
9Erasmus University Medical Centre, Rotterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivagini Ganesh
10University of Southern California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elyse E. Lower
11University of Cincinnati Medical Center, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Engel
12The Christ Hospital, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Wort
2Royal Hospital Brompton, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Price
2Royal Hospital Brompton, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athol U. Wells
2Royal Hospital Brompton, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven D. Nathan
1INOVA Fairfax Hospital, Falls Church, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert P. Baughman
11University of Cincinnati Medical Center, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction Sarcoidosis associated pulmonary hypertension (SAPH) is associated with reduced survival in single center studies. An international registry for SAPH (ReSAPH) with long-term follow-up was established to enrich our knowledge of this complication of sarcoidosis. This analysis aims to elucidate factors associated with reduced transplant-free survival in SAPH patients.

Methods ReSAPH contains prospectively collected outcomes of SAPH patients since the time of registry enrollment. Information analyzed includes right heart catheterization data, pulmonary function testing, chest x-ray Scadding stage, six minute walk distance (6MWD) among others. Cox regression models were used to identify independent predictors of transplant-free survival.

Results Data from a total of 215 patients followed for a mean of 2.5±1.9 years were available for analysis. In the 159 pre-capillary patients, the KM adjusted 1, 3 and 5 year transplant free survival was 89.2%, 71.7% and 62.0%, respectively. In the incident and prevalent groups, KM adjusted 1, 3 and 5 year transplant free survival was 83.5%, 70.3% and 58.3% and 94.7%, 72.2%, and 66.3% respectively. Patients with reduced DLCO (<35% predicted) and 6MWD <300 m in the pre-capillary cohort had significantly worse transplant-free survival. Reduced 6MWD and preserved FEV1/FVC ratio were identified as independent risk factors for reduced transplant-free survival in the pre-capillary cohort.

Conclusion Reduced diffusion capacity (<35% of predicted) and 6MWD <300 m at the time of registry enrollment were associated with reduced transplant-free survival in the overall precapillary cohort. Preserved FEV1/FVC ratio was also identified as an independent risk factor for worsened outcomes.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Shlobin reports personal fees from United Therapeutics, personal fees from Bayer, personal fees from Johnson & Johnson, outside the submitted work.

Conflict of interest: Dr. Kouranos has nothing to disclose.

Conflict of interest: Dr. Barnett has nothing to disclose.

Conflict of interest: Dr. Alhamad has nothing to disclose.

Conflict of interest: Dr. Culver reports other from Gilead, during the conduct of the study; personal fees from Johnson and Johnson, outside the submitted work.

Conflict of interest: Dr. Barney has nothing to disclose.

Conflict of interest: Dr. Cordova has nothing to disclose.

Conflict of interest: Dr. Carmona reports other from Gilead, during the conduct of the study; personal fees from consulting to develop education materials, CHEST, personal fees from editor for Elsevier, outside the submitted work.

Conflict of interest: Dr. Scholand reports other from Boehringer Ingelheim, other from Genentech, other from Fibrogen, other from Global Blood Therapeutics, outside the submitted work; In addition, Dr. Scholand has a patent Apparatus, Compositions and Methods for Assessment of Chronic Obstructive Pulmonary Disease Progression among Rapid and Slow Decline Conditions issued.

Conflict of interest: Dr. wijsenbeek has nothing to disclose.

Conflict of interest: Dr. Ganesh has nothing to disclose.

Conflict of interest: Dr. Lower reports grants from Gilead, grants from Bayer, grants from Genentech, during the conduct of the study.

Conflict of interest: Dr. Engel has nothing to disclose.

Conflict of interest: Dr. Wort reports grants and personal fees from Actelion Pharmaceuticals, grants and personal fees from Bayer Pharmaceuticals, personal fees from MSD, outside the submitted work.

Conflict of interest: Dr. Price reports personal fees and other from Actelion Johnson&Johnson, during the conduct of the study.

Conflict of interest: Dr. Wells reports personal fees from Boeringher Ingelheim, personal fees from Roche, personal fees from Intermune, personal fees from Bayer, outside the submitted work.

Conflict of interest: Dr. Nathan reports personal fees from United Therapeutics, personal fees from Bayer Pharmaceuticals, personal fees from Bellerophon, personal fees from Actelion, during the conduct of the study.

Conflict of interest: Dr. Baughman reports grants from Gilead, grants and personal fees from Actelion, grants from Bayer, grants and personal fees from Mallinckrodt, grants from Genentech, grants from Foundation for sarcoidosis research, grants from National institutes of health, during the conduct of the study.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received September 4, 2019.
  • Accepted February 11, 2020.
  • Copyright ©ERS 2020
PreviousNext
Back to top
View this article with LENS
Vol 59 Issue 6 Table of Contents
European Respiratory Journal: 59 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry
Oksana A. Shlobin, Vasilis Kouranos, Scott D. Barnett, Esam H. Alhamad, Daniel A. Culver, Joseph Barney, Francis C. Cordova, Eva M. Carmona, Mary Beth Scholand, Marlies Wijsenbeek, Sivagini Ganesh, Elyse E. Lower, Peter J. Engel, John Wort, Laura Price, Athol U. Wells, Steven D. Nathan, Robert P. Baughman
European Respiratory Journal Jan 2020, 1901747; DOI: 10.1183/13993003.01747-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry
Oksana A. Shlobin, Vasilis Kouranos, Scott D. Barnett, Esam H. Alhamad, Daniel A. Culver, Joseph Barney, Francis C. Cordova, Eva M. Carmona, Mary Beth Scholand, Marlies Wijsenbeek, Sivagini Ganesh, Elyse E. Lower, Peter J. Engel, John Wort, Laura Price, Athol U. Wells, Steven D. Nathan, Robert P. Baughman
European Respiratory Journal Jan 2020, 1901747; DOI: 10.1183/13993003.01747-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Social consequences of sleep disordered breathing
  • Diagnosing airflow obstruction in COPD
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society